Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Optimal prevention of seizures induced by high-dose busulfanEffect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation.A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patientsProspective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipientsBusulfan in hematopoietic stem cell transplant setting.Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.Impact of obesity on drug metabolism and elimination in adults and children.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Clinical pharmacy service practice in a Chinese tertiary hospital.Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.Dosing algorithm revisit for busulfan following IV infusion.Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.Outcomes after autologous SCT in lymphoma patients grouped by weight.Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients.Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
P2860
Q27687599-B1253170-C2ED-49A5-B253-1890DFDDAECCQ28301571-94019F1F-CE9A-4506-9B6F-E50FC5B376E2Q34409335-FC533B2A-E773-43DE-86CC-05C309A1963CQ34505185-1808212F-8A2B-4F1B-9613-8A8060134C81Q35463268-CC05A4D6-5813-4181-A97C-ABC1431CC584Q35596516-937C706D-669E-4DB7-A7AB-857355C17B0FQ36166109-B714F9C1-071B-47C2-8CCC-1D60765CBA8BQ36881201-86B8D40C-55CE-48DC-92EA-BBA7E7D711DDQ37070285-ECE8D4C4-A6FF-4882-8CD9-E2BB7BF5CFB5Q37554387-20739635-BDF8-4FBA-BF1B-A111088FD6A0Q37624344-25CA1EBE-1732-4228-805E-C2BFE90C69ADQ37940887-7D1780DF-5DF7-4E80-B7EB-634FA2BBDED0Q37997025-13D7445F-9D4D-49ED-8076-BBBA1DC83C68Q38060264-1FAE2E0D-C364-4301-A1D5-169E87DDFB84Q38225489-1CEAEF55-1678-42A2-B0B5-B188B13AFD49Q38604859-D362964A-65E5-4E43-879D-0218597E158EQ41513661-481048A1-3890-4469-BB7F-9F6D87BE2DBAQ41621632-DBC55E7B-C0CD-4878-98FD-0C928FC04FB0Q43194170-89BF9B47-FE1F-49FE-BB4C-2E1A38A46F61Q43291099-D482B622-F65D-4848-9D8B-EC319D2A46BFQ44395207-32404360-943D-4D82-8313-6C1B36293B2BQ44419087-D2A57DE2-AF1F-4208-A566-B0AF2CF9014DQ44693069-A291132B-0880-4310-83F7-3006114B72DBQ47395006-452A36EB-C37A-4566-865D-9A9D7D8EDCA3Q47406671-FC72F30A-A541-4A74-A023-DC0F088C9860Q47825439-2749E5D4-D839-44B4-A6A9-FE3763CE50E5Q48239404-4D3E0197-9140-44AC-AE4C-FEAC03E44E1AQ50802622-02A34E7A-2D90-4F76-B498-41F62814E2C9Q50924228-81CAC43C-0D4C-4E2F-892E-5DB10181140CQ52552920-8E5CB8BB-015A-4ABE-A847-B57C0E9C1996Q58789022-F80D3A0B-3DF8-4D69-AFD6-3A7E75CB981C
P2860
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@en
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@nl
type
label
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@en
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@nl
prefLabel
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@en
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@nl
P2093
P1476
Intravenous busulfan in adults ...... ulation pharmacokinetic study.
@en
P2093
P2888
P304
P356
10.1007/S00280-005-0029-0
P577
2005-08-25T00:00:00Z